BERKELEY, Calif.--(EON: Enhanced Online News)--Aduro BioTech, Inc. announces an oral presentation, entitled “Modified STING-Activating Cyclic Dinucleotide Derivatives Significantly Enhance the Anti-Tumor Activity of Therapeutic Vaccines,” at the upcoming Society for Immunotherapy of Cancer (SITC) annual meeting in National Harbor, Maryland. Thomas W. Dubensky, Jr., chief scientific officer of Aduro, will be presenting at 10:45 am on Saturday, November 9, 2013.
“We are developing small-molecule clinical candidates that activate STING (STimulator of INterferon Genes), a central mediator of the innate immune response”
“We are developing small-molecule clinical candidates that activate STING (STimulator of INterferon Genes), a central mediator of the innate immune response,” said Stephen Isaacs, chairman and chief executive officer at Aduro, “and we’re excited to present our recent progress.”
About Aduro BioTech, Inc.
Aduro BioTech, Inc. is a clinical-stage immunotherapy company located in Berkeley, California. In addition to small molecules that activate STING, the company is developing immunotherapies based on live-attenuated Listeria monocytogenes and on irradiated, GM-CSF-expressing tumor cells. Aduro has completed enrollment in a randomized, controlled Phase 2 clinical trial in patients with metastatic pancreatic cancer and is conducting a Phase 1B trial in patients with malignant pleural mesothelioma. The company’s pipeline includes programs in glioblastoma, non-small-cell lung cancer, ovarian cancer, prostate cancer and malaria.